Vectibix (Panitumumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034

(MENAFN- GlobeNewsWire - Nasdaq) This Vectibix (panitumumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Vectibix (panitumumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.

The key players operating in the vectibix (panitumumab) market is Amgen Inc. North America was the largest region in the vectibix (panitumumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The growth observed in the historical period can be credited to improvements in overall survival rates in clinical trials, favorable reimbursement policies in developed markets, financial assistance programs for patients, educational efforts for oncologists regarding genetic testing, and greater access to advanced diagnostics in developing regions.

Market growth during the forecast period is driven by the increasing prevalence of metastatic colorectal cancer (mCRC) worldwide, a growing emphasis on personalized medicine, rising healthcare spending in emerging markets, higher adoption of biologics in oncology, and a stronger focus on patient quality of life. Key trends during the forecast period include advancements in anti-EGFR therapies, partnerships between pharmaceutical companies, the integration of advanced diagnostic tools, development of companion diagnostics, and the adoption of next-generation sequencing.
The increasing prevalence of colorectal cancer is expected to drive the growth of the vectibix (panitumumab) market in the coming years. Colorectal cancer, which begins in the colon or rectum, is influenced by factors such as aging, genetic predispositions, and environmental influences. The rising incidence of colorectal cancer is linked to an aging population, better survival rates, and improved detection methods.

Vectibix (panitumumab), a monoclonal antibody, targets and inhibits the epidermal growth factor receptor (EGFR) to slow tumor growth and progression in patients with wild-type KRAS tumors. This offers an effective treatment for patients who do not respond to conventional chemotherapy. According to the World Health Organization (WHO), the global burden of colorectal cancer is expected to increase significantly by 2040, with 3.2 million new cases annually, a 63% rise. This growing prevalence is poised to drive the demand for vectibix.
The rising demand for personalized medicine is a key factor propelling the growth of the vectibix (panitumumab) market. Personalized medicine tailors treatments based on individual patient characteristics, including genetic profiles. Advances in genomic technologies, improved understanding of molecular biology, and the availability of precision diagnostic tools have made personalized therapies more common.

Vectibix is used as a personalized treatment for metastatic colorectal cancer by targeting the EGFR on cancer cells, particularly in patients whose tumors express wild-type EGFR. This targeted approach improves therapeutic efficacy and minimizes side effects. For example, in February 2023, the Personalized Medicine Coalition highlighted that the FDA approved several important indications for in vitro diagnostic testing, contributing to the rising demand for personalized medicine. This trend further supports the growth of the vectibix market.
A significant trend in the vectibix market is the development of molecular diagnostic products, such as companion diagnostic kits, which help identify the most suitable patients for targeted therapies. Companion diagnostic kits detect specific biomarkers or genetic mutations, ensuring that treatments like Vectibix are given to patients who are most likely to benefit.

In October 2023, EntroGen Inc. received FDA approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix. This kit, which detects mutations in KRAS and NRAS genes, helps clinicians identify patients who would benefit from Vectibix, ensuring more effective treatment while minimizing unnecessary side effects and costs. This trend towards personalized diagnostics is enhancing the precision of Vectibix therapy and contributing to the market's growth.
Key Topics Covered:
1. Executive Summary
2. Vectibix (panitumumab) Market Characteristics
3. Vectibix (panitumumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route of Administration (ROA)
3.3. Mechanism of Action (MOA)
3.4. Safety and Efficacy
4. Vectibix (panitumumab) Market Trends and Strategies
5. Vectibix (panitumumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
6. Global Vectibix (panitumumab) Growth Analysis and Strategic Analysis Framework
6.1. Global Vectibix (panitumumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis of End Use Industries
6.3. Global Vectibix (panitumumab) Market Growth Rate Analysis
6.4. Global Vectibix (panitumumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)
6.5. Global Vectibix (panitumumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
6.6. Global Vectibix (panitumumab) Total Addressable Market (TAM)
7. Global Vectibix (panitumumab) Market Pricing Analysis & Forecasts
8. Vectibix (panitumumab) Market Segmentation
8.1. Global Vectibix (panitumumab) Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Hospital Pharmacies
• Online Pharmacies

8.2. Global Vectibix (panitumumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Colorectal Cancer Treatment
• Other Cancer Treatments

8.3. Global Vectibix (panitumumab) Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

• Hospitals
• Clinics
• Ambulatory Surgical Centers

9. Global Vectibix (panitumumab) Market Epidemiology of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence and Prevalence of Clinical Indications
10. Vectibix (panitumumab) Market Regional and Country Analysis
10.1. Global Vectibix (panitumumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Vectibix (panitumumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN08052025004107003653ID1109522690